Shots:
Natalie spoke about the study design and key findings from the P-III study evaluating Stelara for the treatment of pediatric patients with active psoriatic arthritis
She also spoke about the patient support program that is executed by Janssen to support patients to get Stelara
The interview gives an understanding of how Janssen is advancing…
Active Ingredients: Ustekinumab
Strength: 45 mg/0.5 mL or 90 mg/mL (SC), 130 mg/26 mL (IV)
Dosage Form: Injection
Mechanism of Action: Interleukin 12 & 23 inhibitor
First Approval: US (25 Sep, 2009), EU (16 Jan, 2009)
Revenue1
Stelara is the leading blockbuster drug of Johnson & Johnson. Stelara contributed 9.7% of the Company's total revenues for 2021. Stelara up took…

